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Abstract: Endothelial nitric oxide synthase (eNOS) plays a major role in maintaining pulmonary vascular ho-
meostasis. Tetrahydrobiopterin (BH4), an essential cofactor that stabilizes the dimerization of eNOS and
balances nitric oxide (NO) and superoxide production, may have therapeutic potential in pulmonary hyperten-
sion. In the isolated perfused lung, we demonstrated a direct effect of exogenous administration of BH4 on
pulmonary NO production, leading to acute vasorelaxation during the plateau phase of hypoxia-induced pul-
monary vasoconstriction. In the chronic hypoxia-induced pulmonary hypertension rat model, chronic BH4
oral administration attenuated the pressor response to hypoxia (mean pulmonary artery pressure  standard
error of the mean, 31.8  0.5 mmHg at 100 mg/kg/day; placebo group, 36.3  0.6 mmHg; P < 0.05). During
telemetric monitoring, right ventricular systolic pressure was reduced by approximately 50% after 1 week of
BH4 treatment at 100 mg/kg/day. BH4 at 100 mg/kg/day reduced right ventricular hypertrophy (from 0.55 
0.01 to 0.50  0.01; P < 0.05) and pulmonary vascular muscularization (from 79.2%  2% to 65.2%  3%;
P < 0.01). BH4 treatment enhanced lung eNOS activity and reduced superoxide production, with a net
increase in cyclic guanosine monophosphate levels. BH4 is effective in attenuating pulmonary hypertension in
the hypoxic rat model when given as a rescue therapy.
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INTRODUCTION
Pulmonary hypertension is a devastating disease character-
ized by pulmonary arterial vasoconstriction and vascular re-
modeling.1-3 The endothelium and, in particular, nitric oxide
synthase (eNOS) play a major role in maintaining normal
pulmonary vascular tone and structure. Dysfunctional eNOS
can imbalance nitric oxide (NO) and superoxide produc-
tion in the pulmonary vasculature, contributing to the path-
ogenesis of pulmonary hypertension.4
Tetrahydrobiopterin (BH4) is an essential cofactor that
regulates eNOS activity. BH4 stabilizes the dimerization of
eNOS, facilitates electron transfer, and balances NO pro-
duction with superoxide generation.5,6 However, in patho-
logical states in which BH4 bioavailability is reduced (e.g.,
oxidized by increased levels of free radicals, such as super-
oxide and peroxynitrite), eNOS becomes dysfunctional and
its activity “uncoupled” to favor superoxide production.7,8
This imbalance in NO/superoxide production results in
oxidative stress, a major contributing factor in a variety of
vascular diseases,7,9,10 which also leads to detrimental ef-
fects on cardiac function.11
Previous studies in our group and others have shown
that BH4 plays a pivotal role in regulating NO/superoxide
balance in the pulmonary vasculature.12-14 It has been
shown that hph-1 mice, deficient in GTP-cyclohydrolase 1
(GTPCH-1), the rate limiting enzyme for BH4 production,
show pulmonary vascular remodeling and right ventricular
hypertrophy under normoxic conditions, accompanied by
significantly increased superoxide production in the lung.
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These mice were also more sensitive to hypoxia exposure
and developed a more severe pulmonary hypertension phe-
notype compared with wild-type mice.
We demonstrated previously that BH4 administration
attenuates the acute pulmonary vasoconstrictor response
to hypoxia in a concentration-dependent manner via NO
and hydrogen peroxide production and showed that BH4
has antioxidant properties.15 This led to the hypothesis that
pharmacological treatment with BH4 may improve pulmo-
nary endothelial function and has therapeutic potential in
pulmonary hypertension. Employing a hypoxia-induced pul-
monary hypertension rat model, we investigated the chronic
pharmacological effects of BH4onhemodynamics, right ven-
tricular hypertrophy, and pulmonary vascular remodeling.
METHODS
Animals
Male Sprague-Dawley (SD) rats (250–350 g) from Charles
River (Margate, UK) were used for all of the experiments.
All studies were conducted in accordance with UK Home
Office Animals (Scientific Procedures) Act 1986.
Acute pharmacologic effects of BH4: the isolated
perfused rat lung
The pulmonary vascular response to 6R-BH4 (sapropterin
dihydochloride or BH4) was studied using the isolated rat
lung preparation as previously described15 (Fig. S1; Figs. S1,
S2 available online). BH4 was supplied by BioMarin Phar-
maceuticals (Novato, CA). Pulmonary artery pressure (PAP)
was measured using a pressure transducer connected to
PowerLab Data Acquisition system (ADInstruments). Hyp-
oxic pulmonary vasoconstriction (HPV) was induced by ven-
tilating the lung with 2% O2, 5% CO2, and 93% N2. BH4
(final concentration, 0.3 μg/mL and 1 μg/mL, freshly pre-
pared as previously described15) or vehicle was added to the
perfusate when consistent HPV had been achieved (usually
after 3 hypoxic challenges). Perfusate samples were col-
lected after passage through the lungs 1 minute before and
3 minutes after BH4 administration for determination of
nitrate/nitrite (NOx) concentration. The effect of BH4 was
calculated from the percentage of change in HPV response
and NOx levels 4 minutes after BH4 administration com-
pared with the HPV response and NOx levels before BH4
administration in the same animal.
Perfusate samples were centrifuged, and the superna-
tant was stored at −20°C. NOx concentration was mea-
sured using an ozone-based chemiluminescence method
by an NO Analyzer (Sievers Model 280).16 Results are pre-
sented as the percentage of the NOx levels after BH4 ad-
ministration in the perfusate compared with the levels be-
fore administration.
Chronic pharmacologic effects of BH4 treatment
SD rats were kept in normobaric hypoxia chamber (10% O2
and 90% N2).
15 BH4 or placebo pellets were given after
2 weeks of hypoxia exposure and continued for an additional
2 weeks under hypoxia. Rats were divided into 5 groups:
(1) normoxia control; (2) 2 weeks hypoxia; (3) 4 weeks hyp-
oxia placebo control; (4) 4 weeks hypoxia with 2 weeks
BH4 low dose (10 mg/kg/day) treatment; and (5) 4 weeks
hypoxia with 2 weeks BH4 high-dose (100 mg/kg/day)
treatment. BH4 pellets were prepared and supplied by Bio-
Marin Pharmaceutical (Novato, CA) in 2 different dos-
ages, 5 and 25 mg/pellet. Placebo pellets were also pre-
pared and included all preservatives and core materials
but without BH4. Rats were fasted 12 hours before the
first dose and 8 hours every 24 hours for the next 2 doses
to encourage compliance with treatment. BH4 pellets were
kept in dark and dry conditions and tested in BioMarin
every 6 months to assess the BH4/dihydrobiopterin (BH2)
content.
Hemodynamic measurements, tissue collection, and
histological examination
Rats were anesthetized (1 ∶ 1 ∶ 2 hypnorm ∶midazolam ∶wa-
ter, 2.7 mL/kg of body weight, administered intraperito-
neally). Right ventricular systolic pressure (RVSP) and PAP
were measured via a precurved catheter inserted through
the right jugular vein, and systemic blood pressure was re-
corded in the carotid artery cannulation using a PowerLab
Data Acquisition system (ADInstruments).
The animals were then killed and tissues were collected,
snap frozen, and stored at −80°C for biochemical mea-
surements. Hearts were dissected and weighed, and the
ratio of right ventricle (RV) to left ventricle plus the sep-
tum mass was used as an index of right ventricular hy-
pertrophy (RVH). The left lung and RV were fixed with
10% formalin in phosphate-buffered saline and processed
for elastic Van Gieson and hematoxylin and eosin (H&E)
staining. Vessels less than 100 μm in peripheral lung were
counted blindly under microscope (40), and pulmonary
vascular remodeling was expressed as the proportion of
vessels with double elastic lamina (>50%) to total vessels
counted (percentage total muscularized vessels).17 Axio-
Vision software (Carl Zeiss) was used to quantifying RV
cardiomyocyte cross section area and myocyte diameter
from transversely cut cardiomyocytes (n  30) using H&E
sections.
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Radiotelemetry
A separate group of rats (n ¼ 4) was implanted with radio-
telemetry monitors (Dataquest A.R.T. 3.1; Data Sciences).
RV pressures were measured by a fluid-filled sensing cath-
eter inserted into the RV through the jugular vein and con-
nected to the transmitter (model TA11PA-40), which sends
the signal to a remote receiver (model RPC-1) and data ex-
changematrix connected to a computer. The pressure wave-
form was monitored online at 30-minute intervals. The
animals were kept in separate cages, and subcutaneous in-
jection of antibiotics (Baytril 5%, 10–20 mg/kg) and anal-
gesics (buprenorphine, 0.1 mL/kg) were administered after
surgery. A week after recovery from surgery, the animals
were put in the hypoxia chamber and monitored daily.
Biochemical measurements
BH4 levels in lung tissue. Measurements of lung tissue
BH4, BH2, and total biopterin were performed by high-
performance liquid chromatography followed by serial elec-
trochemical and fluorescent detection.18 Total biopterins
were quantified by summing BH4, dihydrobiopterin, and bi-
opterin. Biopterin levels were expressed as picomoles per
gram of tissue.
Western blot analysis. Lungs were homogenized. Protein
lysate (20 μg) was resolved in SDS-PAGE and transferred
to nitrocellulose membranes. Purified mouse monoclonal
antibody against human eNOS amino acid 1025–1203
(BD Biosciences, Oxford, UK; 1 ∶ 1,000) and horseradish
peroxidase–conjugated secondary antibodies (1 ∶ 5,000) were
used. The proteins were visualized by chemiluminescence
(GE Healthcare). Optical densities of individual bands were
measured. eNOS expression was normalized to β-actin.
eNOS activity. NOS activity was determined by H3-L-
arginine to H3-L-citrulline conversion using a commer-
cial kit (Cayman Chemical) with minor modifications.19
The integrated H3-L-citrulline elution peak was expressed
as a percentage of total H3 counts. The final results were
normalized to total protein concentration per sample and
expressed as cycles per minute per microgram of protein.
Superoxide levels. Total lung superoxide production was
measured by lucigenin-enhanced chemiluminescence.20
Frozen lungs were homogenized in Krebs-HEPES buffer.
Samples of homogenate corrected for total protein content
were added to 2 mL Krebs-HEPES buffer containing luci-
genin (5 mol/L) in a scintillation vial at 37°C, and chemilu-
minescence was quantified for 5 minutes after measurement
of background. L-NG-nitroarginine methyl ester (1 mM) was
added to the mixture, and the levels of superoxide were
measured for 5 minutes. Superoxide production was ex-
pressed as relative light units per second per milligram dry
weight.
NOx levels. Lung tissue homogenate NOx levels were
measured by a commercial colorimetric assay kit (Cayman
Chemical) according to the manufacturer’s instructions.
Cyclic guanosine monophosphate (cGMP) levels. Lung
tissue samples were homogenized in cold 6% (weight/vol-
ume) trichloroacetic acid. After centrifugation, supernatants
were washed 4 times with water-saturated diethyl ether. The
aqueous extracts were then lyophilized and redissolved in
the assay buffer. cGMP levels were measured by cGMP en-
zyme immunoassay Biotrak System (GE Healthcare) ac-
cording to the manufacturer’s instructions.
Statistical analysis
Results are expressed as mean values  the standard er-
ror of the mean; n equals the number of animals per
experiment. Statistical analysis was performed by using
the Student t test when appropriate, nonparametric test
with Mann-Whitney modification, or 1-way analysis of vari-
ance when applied to multiple group comparisons. A value
of P < 0.05 was considered to be statistically significant.
RESULTS
BH4 induces pulmonary vasodilation at HPV plateau
To examine its acute vasoactive properties, BH4 (0.3 μg/
mL and 1 μg/mL) was administered during the plateau
phase of HPV. BH4 at 1 μg/mL (final perfusate concentra-
tion) induced a significant (35%  5%) decrease in PAP in
comparison with vehicle with a simultaneous increase in
NOx (125%  27%) in the perfusate (Fig. 1).
Pharmacological effects of BH4 on chronic hypoxia–
induced pulmonary hypertension
Radiotelemetry. Continuous radiotelemetric measure-
ment of RVSP showed that pulmonary hypertension was
established after 2 weeks hypoxia exposure (Fig. 2). BH4
(100 mg/kg/day) treatment for 1 week reduced RVSP from
63  4 mmHg to 44.5  4 mmHg in the awake free-living
animal (Fig. 2).
BH4 attenuated PAP and RVSP. Hypoxia exposure for
2 weeks resulted in increases in PAP from 17.8 0.3mmHg
to 33.9  0.6 mmHg and RVSP from 29  1 mmHg to
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59.5  3 mmHg; these levels were maintained at 4 weeks
of hypoxia exposure (PAP, 36.3  1 mmHg; RVSP, 58.2 
3 mmHg). Treatment with BH4 at 100 mg/kg/day from
2 weeks to 4 weeks significantly reduced RVSP (from
59.5  3 mmHg to 45.5  1 mmHg; P < 0.01; Fig. 3A)
and PAP (from 33.9  0.6 mmHg to 31.8  0.5 mmHg;
P < 0.05; Fig. 3B). Systemic blood pressure was not af-
fected by hypoxia or BH4 treatment (Fig. 3D).
BH4 reduces RVH. Hypoxia exposure induced RVH
(Fig. 3C ). Treatment with BH4 at a dosage of 10 mg/kg/
day did not influence RVH. However, BH4 treatment at
100 mg/kg/day significantly attenuated RVH (from 0.58 
0.0 mmHg to 10.50 0.01 mmHg; P < 0.05; Fig. 3C ), and
this was associated with significant reduction in cardio-
myocyte diameter in comparison with 4 weeks hypoxia-
placebo treatment (24.9  0.5 μm to 21.1  0.5 μm; P <
0.05) and a significant reversal compared with 2 weeks
hypoxia (23.5 0.7 μm to 21.1  0.5 μm; P < 0.05; Fig. 4).
BH4 reverses pulmonary vascular muscularization. Pulmo-
nary muscularization was significantly increased in rats
exposed to 2 weeks of hypoxia compared with normoxia
controls (79.2%  2% vs. 15.6%  1%; P < 0.01). Treat-
ment with placebo or BH4 at a dosage of 10 mg/kg/day
did not affect muscularization (81.4%  3% and 74.3% 
5%, respectively), but BH4 at a dosage of 100 mg/kg/day
induced significant reduction in vascular muscularization
(65.2%  3%) compared with 2 weeks hypoxia alone or
4 weeks hypoxia alone (P < 0.01; Fig. 5).
Lung tissue BH4 levels. BH4 treatment did not influence
lung homogenate BH4 levels in comparison with placebo
or control (Table S1, available online).
Effects of BH4 on eNOSprotein levels and enzyme activity
eNOS protein levels were increased after 2 weeks of hyp-
oxia and returned to normal levels after 4 weeks of hypoxia.
Neither placebo nor BH4 treatment had any significant in-
fluence on eNOS protein expression in lung homogenates
(Fig. 6A). eNOS activity in lung homogenates from the
BH4 100 mg/kg/day treatment group was increased signifi-
cantly in comparison with control, 2 weeks hypoxia, 4 weeks
hypoxia-placebo, or 4 weeks hypoxia-BH4 (10 mg/kg/day;
Fig. 6B).
Effects of BH4 on cGMP, NOx, and superoxide levels
There was an increased cGMP level in lung homoge-
nates with BH4 treatment (100 mg/kg/day) compared
with placebo-treated group (Fig. 7; P < 0.01). NOx levels
were increased in all hypoxic groups in comparison with
Figure 1. A, Representative pulmonary artery pressure (PAP)
trace illustrating the protocol for tetrahydrobiopterin (BH4) ad-
ministration during the stable phase of hypoxic pulmonary va-
soconstriction (HPV) response in the rat isolated perfused lung.
B, The effect of BH4 on PAP during HPV response. The effect of
BH4 was calculated as the PAP reduction (ΔPAP) 3 minutes after
drug administration expressed as a percentage of the maximum
HPV response (HPVmax) in the same hypoxia challenge (black
bars). Nitric oxide production was calculated as the percentage of
the nitrate/nitrite (NOx) levels after BH4 administration in the
perfusate compared with the levels before administration (n ¼ 5).
Figure 2. Tetrahydrobiopterin (BH4) treatment reverses pulmo-
nary hypertension in rat hypoxia model. Effect of BH4 on right
ventricular systolic pressure (RVSP) in hypoxia-induced pulmo-
nary hypertension rat model measured by telemetry. Hypoxia
was started on day 0; BH4 treatment was started on day 14 and
continued for 1 week.
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control levels without significant differences in the BH4-
treated group compared with placebo.
BH4 (100 mg/kg/day) significantly reduced the total su-
peroxide levels in the lung homogenates. Furthermore, the
fraction of eNOS-generated superoxide production was at-
tenuated in the BH4-treated group compared with placebo
(P ¼ 0.054; Fig. 7).
DISCUSSION
This study examined the effects of oral BH4 supplementa-
tion on hemodynamics, RVH, and pulmonary vascular re-
modeling in the chronic hypoxia-induced pulmonary hyper-
tension rat model. We demonstrated that BH4 treatment
(a) attenuated the increase in PAP and improved cardiac
hemodynamics in this model and (b) reduced established
pulmonary vascular muscularization andmyocardial hyper-
trophy. Coincident with this, lung superoxide production
was reduced, and cGMP levels were increased.
Pulmonary hypertension is a disease with a complex eti-
ology. Dysfunctional endothelium and, in particular, eNOS
activity that results in impaired NO and increased super-
oxide production is well documented and contributes to
pulmonary vasoconstriction, excessive pulmonary vascular
cell proliferation, inflammation, right ventricular dysfunc-
tion, and failure.2,4,21 Our previous observation that hph-1
mice exhibit a pulmonary hypertension phenotype under
normoxia without overt systemic hypertension emphasized
the essential role of BH4 in the regulation of the pulmo-
nary circulation.12-14 BH4 therapy as a tool for manipulat-
ing NOS “uncoupling” has been explored extensively in
a variety of cardiovascular diseases. BH4 supplementation
can reverse endothelial pathophysiology by enhancing NO
bioavailability and ameliorating oxidative stress.
Pulmonary hypertension has been a particular benefi-
ciary of treatments developed for enhancing NO/cGMP sig-
naling. These include currently approved clinical treatments,
such as NO inhalation22,23 and PDE5 inhibitors,24,25 and
more recently soluble gyuanylate cyclase stimulators. Our
data from the isolated perfused lungs demonstrate a direct
effect of exogenous BH4 administration on pulmonary NO
production during hypoxic ventilation, leading to acute vaso-
relaxation during the plateau phase of hypoxia-induced pul-
monary vasoconstriction. Exposing rats to chronic hypoxia
induces an increase in PAP that peaks at around 2 weeks.26
Using radiotelemetry, we were able to examine the tempo-
ral relationship between BH4 administration and pulmo-
Figure 3. Treatment with tetrahydrobiopterin (BH4) or placebo was started 2 weeks (W) after chronic hypoxia exposure and con-
tinued for another 2 W. Right ventricular systolic pressure (RVSP; A), mean pulmonary artery pressure (mPAP; B), and right ven-
tricular over left ventricular and septum weight ratio (RV/LV+septum; C ) in different groups are shown. In addition, the effect of
hypoxia and drug treatment on mean systemic blood pressure (mBP) is presented in D. Asterisk: P < 0.05 compared with hypoxia
placebo; dollar sign: P < 0.05 compared with 2 W hypoxia; double dollar sign: P < 0.01 compared with 2 W hypoxia; pound sign: P < 0.05
compared with control (n ¼ 6–10 per group).
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nary pressure. A significant reduction in RVSP was ob-
served (approximately 52%) after 1 week of treatment. West-
ern blotting of lung homogenates revealed increased eNOS
expression after 2 weeks of hypoxia exposure and a main-
tained baseline eNOS expression (similar to normoxia
controls) after 4 weeks of hypoxia exposure. Preserved or
increased lung eNOS expression after hypoxia exposure has
also been reported by the other groups,27-29 which contrasts
with the impairment of NO bioavailability in pulmonary
hypertension. One possibility is a decrease in eNOS activity,
as observed in isolated pulmonary arteries from rats ex-
posed to hypoxia.30 Interestingly, although dosing the rats
with BH4 after 2 weeks of hypoxia did not affect eNOS
expression, it enhanced lung eNOS activity.
There is increasing evidence of oxidative stress in pul-
monary hypertension,31,32 exemplified by nitrotyrosine for-
mation (a marker of peroxynitrite production) in the lungs
Figure 4. The effect of tetrahydrobiopterin (BH4) on distal lung vascular muscularization. A, Histological pictures taken to show
the double elastic lamina seen with Van Gieson staining as indication for muscularized vessels. Notice the double elastic lamina
with placebo-treated group, which is thinner in BH4 10 mg/kg and almost reduced to 1 elastic lamina in 100 mg/kg. Treatment
with BH4 at a dosage of 100 mg/kg reversed lung vascular muscularization compared with placebo as well as 2 weeks (W) of
hypoxia (the starting point of treatment; B). Three asterisks: P < 0.001 compared with 4 W of placebo treatment and 2 W of
hypoxia; pound sign: P < 0.05 compared with control (n ¼ 6 per group).
Figure 5. Myocyte diameter is measured in right ventricle (RV)
sections in different groups as an index of RV hypertrophy. Two
asterisks: P < 0.01 compared with placebo; dollar sign: P <
0.05 compared with 2 weeks (W) of hypoxia; pound sign: P <
0.05 compared with control (n ¼ 5–8 per group); BH4: tetra-
hydrobiopterin.
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Figure 6. Illustration of the effects of tetrahydrobiopterin (BH4) treatment on levels of endothelial nitric oxide synthase (eNOS)
protein expression (A; n ¼ 6–8 per group) and eNOS activity (B; n ¼ 4–8 per group) in lung homogenates in hypoxia recovery
protocol. Pound sign: P < 0.05 compared with control; asterisk: P < 0.05 compared with 4 weeks (W) hypoxia placebo.
Figure 7. Effects of tetrahydrobiopterin (BH4) recovery treatment on cyclic guanosine monophosphate (cGMP; n ¼ 6–8 per group;
A), nitrate/nitrite (NOx; n ¼ 5–8 per group; B), superoxide (n ¼ 6–8 per group; C ), and endothelial nitric oxide synthase (eNOS)–
related superoxide levels (n ¼ 6–8; D) in lung homogenates in hypoxia recovery study. BH4 treatment did increase the levels of
cGMP compared with the placebo-treated group but not to a statistically significant value. Nitric oxide levels were increased in all
hypoxic groups in a similar manner. RLU: relative light units; pound sign: P < 0.05; two pound signs: P < 0.01 compared with
control.
of patients with the disease.33 Vascular superoxide produc-
tion has a number of important actions on vascular tissue,
such as NO scavenging, peroxynitrite formation, and modu-
lation of redox-sensitive signalling pathways,7,9,10 which
may adversely affect vascular tone and structure. Further-
more, superoxide and peroxynitrite may oxidize BH4, and
enhanced oxidative degradation is thought to be a major
cause of reduced BH4 bioavailability and eNOS uncoupling
in endothelial dysfunction states.34-36 Our data show that
BH4 treatment significantly reduced total superoxide levels
and, in particular, the fraction of eNOS-associated superox-
ide production in the lung. This fits well with our under-
standing of BH4-eNOS coupling. In addition, it is possible
that exogenous BH4 acted as an antioxidant and scavenged
reactive oxygen species such as superoxide.15
The effect of BH4 was dose dependent. BH4, admin-
istered at 100 mg/kg/day, effectively reduced pulmonary
pressure, RVH, and pulmonary muscularization, whereas
BH4 at 10 mg/kg/day did not have any significant effect.
One possibility is that there was oxidation of active BH4
to inactive BH2 during hypoxia, thereby reducing expo-
sure to the active molecule.37-39 This idea is consistent
with previous findings that endothelial BH4 levels deter-
mine the susceptibility of mice to hypoxia-induced pulmo-
nary hypertension; although BH4-deficient hph-1 mice are
more susceptible, mice with GTPCH-1 overexpression for
BH4 production are protected.
12-14 In this study, we mea-
sured lung biopterin (BH4, BH2) levels, but the measure-
ments were challenging, and there were no significant
changes with BH4 treatment. Our understanding of how
oral BH4 supplements reach the targeted tissue is still
limited. Indeed, a recent clinical trial with oral BH4 treat-
ment in coronary artery disease exhibited a concomitant
increase in plasma BH2 levels, but BH4-eNOS coupling
was tempered by BH4 oxidation, BH2 accumulation, and
failure to increase BH4/BH2 ratio.
40 This will complicate
the future clinical application of BH4 as a treatment un-
less more stable BH4 analogs can be used.
41
Nonetheless, the data from this study indicate that BH4
is effective in reversing pulmonary hypertension in a hyp-
oxic rat model when given as a rescue therapy. Encourag-
ing results also come from our recent clinical safety study
of BH4 in patients with pulmonary arterial hypertension,
where BH4 treatment at a dosage of 5 mg/kg/day was as-
sociated with a positive signal, an increase in 6-minute
walk distance, and reduced plasma levels of monocyte che-
moattractant protein 1.42 Collectively, these data suggest
that BH4 supplementation has therapeutic potential for
pulmonary hypertension.
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